Repository logo
 
Publication

IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis.

2014Journal article Restricted access
Simple item page
dc.contributor.authorCravo, M
dc.contributor.authorFerreira, P
dc.contributor.authorSousa, P
dc.contributor.authorMoura-Santos, P
dc.contributor.authorVelho, S
dc.contributor.authorTavares, L
dc.contributor.authorDeus, JR
dc.contributor.authorMinistro, P
dc.contributor.authorPeixe, P
dc.contributor.authorCorreia, L
dc.contributor.authorVelosa, J
dc.contributor.authorMaio, R
dc.contributor.authorBrito, M
dc.date.accessioned2015-01-23T15:12:06Z
dc.date.available2015-01-23T15:12:06Z
dc.date.issued2014
dc.description.abstractOBJECTIVE: We aimed to identify the clinical and genetic [IL23 receptor (IL23R) single nucleotide polymorphisms (SNPs)] predictors of response to therapy in patients with ulcerative colitis. PATIENTS AND METHODS: A total of 174 patients with ulcerative colitis, 99 women and 75 men, were included. The mean age of the patients was 47±15 years and the mean disease duration was 11±9 years. The number of patients classified as responders (R) or nonresponders (NR) to several therapies was as follows: 110 R and 53 NR to mesalazine (5-ASA), 28 R and 20 NR to azathioprine (AZT), 18 R and 7 NR to infliximab. Clinical and demographic variables were recorded. A total of four SNPs were studied: IL23R G1142A, C2370A, G43045A, and G9T. Genotyping was performed by real-time PCR using Taqman probes. RESULTS: Older patients were more prone to respond to 5-ASA (P=0.004), whereas those with pancolitis were less likely to respond to such therapies (P=0.002). Patients with extraintestinal manifestations (EIMs) were less likely to respond to 5-ASA (P=0.001), AZT (P=0.03), and corticosteroids (P=0.06). Carriers of the mutant allele for IL23R SNPs had a significantly higher probability of developing EIMs (P<0.05), a higher probability of being refractory to 5-ASA (P<0.03), but a higher likelihood of responding to AZT (P=0.05). A significant synergism was observed between IL23R C2370A and EIMs with respect to nonresponse to 5-ASA (P=0.03). CONCLUSION: Besides extent of disease and age at disease onset, the presence of EIMs may be a marker of refractoriness to 5-ASA, corticosteroids, and AZT. IL23R SNPs are associated both with EIMs and with nonresponse to 5-ASA and corticosteroids.por
dc.identifier.citationEur J Gastroenterol Hepatol. 2014 Jan;26(1):26-32por
dc.identifier.doi10.1097/MEG.0000000000000004
dc.identifier.urihttp://hdl.handle.net/10400.10/1344
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherLippincott Williams And Wilkinspor
dc.subjectUlcerative colitispor
dc.subjectAnti-Inflammatory agentspor
dc.subjectColite ulcerosapor
dc.subjectAnti-inflamatóriospor
dc.titleIL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis.por
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceLondonpor
oaire.citation.endPage32por
oaire.citation.startPage26por
oaire.citation.titleEuropean Journal of Gastroenterology and Hepatologypor
oaire.citation.volume26por
rcaap.rightsopenAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Eur J Gastroenterol Hepatol. 2014 Jan 26(1) 26-32.pdf
Size:
355.4 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

GAS - Artigos publicados em revistas indexadas